PGE2 inhibits DC maturation and migration in tumor‐draining lymph node and TME, affects naïve T cell priming by inducing the loss of IRF8 and skewing DC phenotype toward cDC2, by inducing expression of IDO‐1 and CD25, two inhibitors of CD8+ T‐cell activity, and by promoting DC production of IL‐10. Here, IRF8 is linked to neoplasm.